This Bulletin Covers Aspects of Lymphomas and Should Be of Interest to Multidisciplinary

Lymphomas May 2015

This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in this area.

Sections can include:  Combined Modality Therapies  Drug & Biological Therapies  Pathology, Staging, Polymorphisms & Biomarkers  Prognosis, Survival & Risk Factors  Radiotherapy & Imaging  Stem Cell Transplantation  Supportive Care & Symptom Management

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by: Kirsty Coltart Subject Librarian Beatson West of Scotland Cancer Centre 0141 301 7285, [email protected]

General

Bachy E and Salles G. (2015). Treatment approach to newly diagnosed diffuse large B-cell lymphoma. Seminars in hematology 52,2:107-118.

Cardenas-Garcia J, Talwar A, Shah R, et al. (2015). Update in primary pulmonary lymphomas. Current opinion in pulmonary medicine 21,4:333-337.

Cheah CY, Oki Y, Westin JR, et al. (2015). A clinician's guide to double hit lymphomas. British journal of haematology 168,6:784-795.

Moriarty B and Whittaker S. (2015). Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma. Expert Review of Hematology 8,2:159-171.

Mussetti A, Kumar A, Dahi PB, et al. (2015). Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood reviews 29,3:143-152.

Nazeef M and Kahl BS. (2015). Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. Current Treatment Options in Oncology 16,6:343.

Nicolas M and Christian G. (2015). Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. Expert Review of Hematology 8,2:205-216.

Stienen JJ, Ottevanger PB, Wennekes L, et al. (2015). Trends in quality of non-Hodgkin's lymphoma care: is it getting better?. Annals of Hematology 94,7:1195-1203.

Tevlin R, Larkin JO, Hyland JM, et al. (2015). Primary colorectal lymphoma - A single centre experience. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland 13,3:151-155.

Xie H, Ahluwalia MS and Peereboom DM. (2015). The Cleveland Clinic experience with primary central nervous system lymphoma. American Journal of Clinical Oncology 38,2:140-146.

Zelenetz AD, Gordon LI, Wierda WG, et al. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network 13,3:326-362.

Combined Modality Therapies

Berinstein NL, Bhella S, Pennell NM, et al. (2015). Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Annals of Hematology 94,5:813-823.

Bonthapally V, Wu E, Macalalad A, et al. (2015). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Current Medical Research & Opinion 31,5:993-1001.

He G, Wang C, Tan H, et al. (2015). Rituximab after autologous stem cell transplantation enhances survival of B-cell lymphoma patients: a meta-analysis and systematic review. Transplantation proceedings 47,2:517-522.

Illidge T, Bouabdallah R, Chen R, et al. (2015). Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia & lymphoma 56,3:703-710.

Jegadeesh N, Rajpara R, Esiashvili N, et al. (2015). Predictors of Local Recurrence After Rituximab- Based Chemotherapy Alone in Stage III and IV Diffuse Large B-Cell Lymphoma: Guiding Decisions for Consolidative Radiation. International journal of radiation oncology, biology, physics 92,1:107-112.

Kirschey S, Flohr T, Wolf HH, et al. (2015). Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. British journal of haematology 168,6:824-834.

Moskowitz CH, Nademanee A, Masszi T, et al. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385,9980:1853-1862.

Drug & Biological Therapies

Alinari L, Quinion C and Blum KA. (2015). Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas. Clinical Pharmacology & Therapeutics 97,5:469-477.

Alwan F, He A, Montoto S, et al. (2015). Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. AIDS 29,8:903-910.

Ansell, S. (2015). Novel agents in the therapy of hodgkin lymphoma. American Society of Clinical Oncology Educational Book 35,e479-82.

Behringer K, Goergen H, Hitz F, et al. (2015). Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385,9976:1418-1427.

Cheah CY, Chihara D, Romaguera JE, et al. (2015). Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Annals of Oncology 26,6:1175-1179.

Chen R, Frankel P, Popplewell L, et al. (2015). A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica 100,3:357-362.

Czuczman MS, Kahanic S, Forero A, et al. (2015). Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Annals of Hematology 94,4:633- 641.

Foss F, Advani R, Duvic M, et al. (2015). A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. British journal of haematology 168,6:811-819.

Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, et al. (2015). Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study. Acta Oncologica 54,6:939-943.

Hosein PJ, Sandoval-Sus JD, Goodman D, et al. (2015). Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. American Journal of Hematology 90,6:E111-6.

Huang J, Fairbrother W and Reed JC. (2015). Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies. Expert Review of Hematology 8,3:283-297.

Ishida T, Jo T, Takemoto S, et al. (2015). Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. British journal of haematology 169,5:672-682.

Jung SH, Lee JJ, Kim WS, et al. (2015). Weekly rituximab consolidation following four cycles of R- CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). European journal of haematology 94,6:504-510.

Liewer S and Huddleston AN. (2015). Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients. Expert Review of Anticancer Therapy 15,4:453-464.

Mondello P and Younes A. (2015). Emerging drugs for diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy 15,4:439-451.

Moskowitz AJ, Schoder H, Yahalom J, et al. (2015). PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncology 16,3:284-292.

Robak T, Huang H, Jin J, et al. (2015). Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. New England Journal of Medicine 372,10:944-953.

Rueda A, Garcia-Sanz R, Pastor M, et al. (2015). A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. Acta Oncologica 54,6:933-938.

Sarkozy C, Salles G and Bachy E. (2015). Chemotherapy-free treatment in patients with follicular lymphoma. Expert Review of Hematology 8,2:187-203.

Siddiqi T and Rosen ST. (2015). Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1. Oncology (Williston Park) 29,3:198-203.

Siddiqi T and Rosen ST. (2015). Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology (Williston Park) 29,4:299-308.

Skarbnik AP and Goy AH. (2015). Lenalidomide for mantle cell lymphoma. Expert Review of Hematology 8,3:257-264.

Smithson CR and Schneider SM. (2015). Ibrutinib: a new targeted therapy for hematologic cancers. Clinical journal of oncology nursing 19,3:E47-51.

Ujjani C, Ramzi P, Gehan E, et al. (2015). Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia & lymphoma 56,4:915- 920.

Wasle I, Gamerith G, Kocher F, et al. (2015). Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. Annals of Hematology 94,4:593-601.

Pathology, Staging, Polymorphisms & Biomarkers

Boi M, Zucca E, Inghirami G, et al. (2015). Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. British journal of haematology 168,6:771-783.

Castillo JJ, Chavez JC, Hernandez-Ilizaliturri FJ, et al. (2015). CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Review of Hematology 8,3:343-354.

Dalley C, Basarir H, Wright JG, et al. (2015). Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. Journal of clinical pathology 68,4:292-300.

Dunleavy K and Steidl C. (2015). Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma. Seminars in hematology 52,2:119-125.

Jiang Y and Melnick A. (2015). The epigenetic basis of diffuse large B-cell lymphoma. Seminars in hematology 52,2:86-96.

Nardi V, Pulluqi O, Abramson JS, et al. (2015). Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. American Journal of Hematology 90,6:529-533.

Nowakowski GS and Czuczman MS. (2015). ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. American Society of Clinical Oncology Educational Book 35,e449-57.

Pasqualucci L and Dalla-Favera R. (2015). The genetic landscape of diffuse large B-cell lymphoma. Seminars in hematology 52,2:67-76.

Schmidt MT, Huang Q and Alkan S. (2015). Aggressive B-cell lymphomas: a review and practical approach for the practicing pathologist. Advances in Anatomic Pathology 22,3:168-180.

Scott, D.W. (2015). Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?. American Society of Clinical Oncology Educational Book 35,e458-66.

Young RM, Shaffer AL 3rd, Phelan JD, et al. (2015). B-cell receptor signaling in diffuse large B-cell lymphoma. Seminars in hematology 52,2:77-85.

Prognosis, Survival & Risk Factors

Belotti A, Doni E, Bolis S, et al. (2015). Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Clinical lymphoma, myeloma & leukemia 15,4:208-213.

Fisher RI and Khan N. (2015). Is observation dead in follicular lymphoma? No, but the apoptosis pathway has been activated. Journal of the National Comprehensive Cancer Network 13,3:363-366.

Issa DE, van de Schans SA, Chamuleau ME, et al. (2015). Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica 100,4:525-533.

Jacobson CA and Freedman AS. (2015). Is observation dead in follicular lymphoma? Still appropriate. Journal of the National Comprehensive Cancer Network 13,3:367-370.

Kelly JL, Salles G, Goldman B, et al. (2015). Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. Journal of Clinical Oncology 33,13:1482-1490.

Marcheselli L, Bari A, Anastasia A, et al. (2015). Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. British journal of haematology 169,4:544-551.

Nijeboer P, de Baaij LR, Visser O, et al. (2015). Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. American Journal of Hematology 90,6:493-498.

Shah BK, Bista A and Shafii B. (2015). Disparities in receipt of radiotherapy and survival by age, sex and ethnicity among patients with stage I diffuse large B-cell lymphoma. Leukemia & lymphoma 56,4:983-986.

Teckie S, Qi S, Lovie S, et al. (2015). Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. International journal of radiation oncology, biology, physics 92,1:130-137.

Terret C, Albrand G, Rainfray M, et al. (2015). Impact of comorbidities on the treatment of non- Hodgkin's lymphoma: a systematic review. Expert Review of Hematology 8,3:329-341.

Radiotherapy & Imaging

Crump M, Herst J, Baldassarre F, et al. (2015). Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma. Blood 125,11:1708-1716.

Ganesan P, Rajendranath R, Kannan K, et al. (2015). Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Annals of Oncology 26,6:1170-1174.

Heumann TR, Esiashvili N, Parker S, et al. (2015). Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique. International journal of radiation oncology, biology, physics 92,1:183-191.

Hoppe BS and Hoppe RT. (2015). Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of hodgkin lymphoma. International journal of radiation oncology, biology, physics 92,1:40-45.

King MT, Donaldson SS, Link MP, et al. (2015). Management of nodular lymphocyte predominant hodgkin lymphoma in the modern era. International journal of radiation oncology, biology, physics 92,1:67-75.

Korfel A, Thiel E, Martus P, et al. (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 84,12:1242-1248.

Kriz J, Reinartz G, Dietlein M, et al. (2015). Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. International journal of radiation oncology, biology, physics 92,1:46-53.

Maraldo MV, Dabaja BS, Filippi AR, et al. (2015). Radiation therapy planning for early-stage hodgkin lymphoma: experience of the international lymphoma radiation oncology group. International journal of radiation oncology, biology, physics 92,1:144-152.

Pinnix CC, Dabaja B, Ahmed MA, et al. (2015). Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. International journal of radiation oncology, biology, physics 92,1:113-121.

Radford J, Illidge T, Counsell N, et al. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. New England Journal of Medicine 372,17:1598-1607.

Rigacci L, Puccini B, Zinzani PL, et al. (2015). The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). American Journal of Hematology 90,6:499-503.

Torok JA, Wu Y, Prosnitz LR, et al. (2015). Low-dose consolidation radiation therapy for early stage unfavorable hodgkin lymphoma. International journal of radiation oncology, biology, physics 92,1:54- 59.

Special Populations

Dharmarajan KV, Friedman DL, Schwartz CL, et al. (2015). Patterns of Relapse From a Phase 3 Study of Response-Based Therapy for Intermediate-Risk Hodgkin Lymphoma (AHOD0031): A Report From the Children's Oncology Group. International journal of radiation oncology, biology, physics 92,1:60-66.

El-Mallawany NK and Cairo MS. (2015). Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clinical Advances in Hematology & Oncology 13,2:113- 123.

Eyre TA, Lau IJ, Mackillop L, et al. (2015). Management and controversies of classical Hodgkin lymphoma in pregnancy. British journal of haematology 169,5:613-630.

Giulino-Roth L, Keller FG, Hodgson DC, et al. (2015). Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. British journal of haematology 169,5:647-660.

Hodgson DC, Dieckmann K, Terezakis S, et al. (2015). Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Practical Radiation Oncology 5,2:85-92.

Kontny U, Oschlies I, Woessmann W, et al. (2015). Non-anaplastic peripheral T-cell lymphoma in children and adolescents--a retrospective analysis of the NHL-BFM study group. British journal of haematology 168,6:835-844.

Morrison VA, Hamlin P, Soubeyran P, et al. (2015). Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. Journal of Geriatric Oncology 6,2:141-152.

Olszewski AJ, Shafqat H and Ali S. (2015). Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. Leukemia & lymphoma 56,4:942-950.

Pulczynski EJ, Kuittinen O, Erlanson M, et al. (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica 100,4:534-540.

Sekimizu M, Mori T, Kikuchi A, et al. (2015). Prognostic impact of cytogenetic abnormalities in children and adolescents with mature B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatric Blood & Cancer 62,7:1294-1296.

Supportive Care & Symptom Management

Hodgson, D.C. (2015). Long-term toxicity of chemotherapy and radiotherapy in lymphoma survivors: optimizing treatment for individual patients. Clinical Advances in Hematology & Oncology 13,2:103-112.

Pinnix CC, Smith GL, Milgrom S, et al. (2015). Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for hodgkin and non-hodgkin lymphoma. International journal of radiation oncology, biology, physics 92,1:175-182.

Wagner LI, Zhao F, Hong F, et al. (2015). Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Journal of Clinical Oncology 33,7:740- 748.

Zhou X, Wang J, Zhang J, et al. (2015). Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology 20,3:129-136.

Transplantation

Cohen JB, Burns LJ and Bachanova V. (2015). Role of allogeneic stem cell transplantation in mantle cell lymphoma. European journal of haematology 94,4:290-297.

Kim MG, Han N, Lee EK, et al. (2015). Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone marrow transplantation 50,4:523-530.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin. Sources used for this bulletin:

OVID MEDLINE, SIGN, NICE and Healthcare Improvement Scotland